| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $2,362,652 | 2 | 100 |
| RAMSAY DAVID A | director | 0 | $0 | 1 | $121,220 | $-121,220 |
| Lowrance David L | Chief Financial Officer | 0 | $0 | 1 | $2.24M | $-2.24M |
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Over the last 12 months, insiders at Savara Inc. have bought $0 and sold $2.36M worth of Savara Inc. stock.
On average, over the past 5 years, insiders at Savara Inc. have bought $4.04M and sold $1.18M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 48,225 shares for transaction amount of $98,572 was made by Hawkins Richard J (director) on 2025‑06‑20.
| 2026-06-22 | Sale | Lowrance David L | Chief Financial Officer | 394,528 0.1989% | $5.68 | $2.24M | -5.54% | |
| 2025-12-19 | Sale | RAMSAY DAVID A | director | 20,000 0.0098% | $6.06 | $121,220 | -10.99% | |
| 2025-06-20 | Hawkins Richard J | director | 48,225 0.0277% | $2.04 | $98,572 | +146.84% | ||
| 2025-05-29 | McCracken Joseph S | director | 10,000 0.0054% | $2.08 | $20,825 | +119.64% | ||
| 2025-03-31 | RAMSAY DAVID A | director | 150,000 0.0876% | $2.77 | $416,250 | +28.88% | ||
| 2024-12-16 | Sale | Pauls Matthew | CHIEF EXECUTIVE OFFICER | 54,702 0.0322% | $3.31 | $180,828 | -8.59% | |
| 2024-12-16 | Sale | Lowrance David L | Chief Financial Officer | 25,000 0.0148% | $3.33 | $83,278 | -8.59% | |
| 2024-12-16 | Sale | Hawkins Richard J | director | 8,000 0.0047% | $3.32 | $26,569 | -8.59% | |
| 2024-11-19 | McCracken Joseph S | director | 20,000 0.0117% | $2.95 | $59,072 | +1.36% | ||
| 2024-11-18 | RAMSAY DAVID A | director | 100,000 0.0566% | $2.88 | $287,600 | -0.17% | ||
| 2023-12-28 | Sale | Pauls Matthew | CHIEF EXECUTIVE OFFICER | 84,000 0.0609% | $4.71 | $395,900 | -9.75% | |
| 2023-12-28 | Sale | Lowrance David L | CHIEF FINANCIAL OFFICER | 10,000 0.0072% | $4.71 | $47,131 | -9.75% | |
| 2023-12-28 | Sale | Elam Nevan C | director | 93,843 0.068% | $4.71 | $442,291 | -9.75% | |
| 2023-07-17 | Yang Rick | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | Walker Paul Edward | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | SANDELL SCOTT D | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | Mathers Edward T | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | Makhzoumi Mohamad | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | Growth Equity Opportunities 17, LLC | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | Florence Anthony A. Jr. | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% |
| RAMSAY DAVID A | director | 2533642 1.2332% | $12.03M | 53 | 1 | +45.15% |
| Lowrance David L | Chief Financial Officer | 536032 0.2609% | $2.55M | 3 | 13 | +23.24% |
| SANDELL SCOTT D | 10 percent owner | 24471264 11.9105% | $116.24M | 1 | 0 | +32.8% |
| BASKETT FOREST | 10 percent owner | 24471264 11.9105% | $116.24M | 1 | 0 | +32.8% |
| Mathers Edward T | 10 percent owner | 24471264 11.9105% | $116.24M | 1 | 0 | +32.8% |
| Walker Paul Edward | 10 percent owner | 24471264 11.9105% | $116.24M | 1 | 0 | +32.8% |
| Florence Anthony A. Jr. | 10 percent owner | 24471264 11.9105% | $116.24M | 1 | 0 | +32.8% |
| Behbahani Ali | 10 percent owner | 24471264 11.9105% | $116.24M | 1 | 0 | +32.8% |
| Makhzoumi Mohamad | 10 percent owner | 24471264 11.9105% | $116.24M | 1 | 0 | +32.8% |
| Chang Carmen | 10 percent owner | 24471264 11.9105% | $116.24M | 1 | 0 | +32.8% |
| Growth Equity Opportunities 17, LLC | 10 percent owner | 24471264 11.9105% | $116.24M | 1 | 0 | +32.8% |
| Yang Rick | 10 percent owner | 24471264 11.9105% | $116.24M | 1 | 0 | +32.8% |
| LEVINE EVAN | CEO & President | 4395000 2.1391% | $20.88M | 13 | 7 | |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER | 1536379 0.7478% | $7.3M | 10 | 2 | <0.0001% |
| Neville Robert N | Chief Executive Officer | 498028 0.2424% | $2.37M | 2 | 4 | +85.25% |
| McCracken Joseph S | director | 260837 0.127% | $1.24M | 4 | 0 | +44.92% |
| Chowdhury Badrul A. | CHIEF MEDICAL OFFICER | 175000 0.0852% | $831,250.00 | 1 | 1 | +24.29% |
| Jouhikainen Jaakko Taneli | President and COO | 167569 0.0816% | $795,952.75 | 1 | 7 | +85.25% |
| Pratt Raymond Dennis | Chief Medical Officer | 160000 0.0779% | $760,000.00 | 2 | 0 | +81.8% |
| PIKOVER YURI | director | 153734 0.0748% | $730,236.50 | 3 | 0 | +39.18% |
| Hawkins Richard J | director | 115466 0.0562% | $548,463.50 | 1 | 3 | +146.84% |
| Roberts Brandi | Chief Financial Officer & SVP | 38000 0.0185% | $180,500.00 | 2 | 0 | |
| MERRITT JAMES A | President & Chf Med Officer | 35000 0.017% | $166,250.00 | 1 | 0 | |
| Culley Brian M | CEO and Director | 34500 0.0168% | $163,875.00 | 3 | 1 | |
| ROBBINS JOAN M | CSO, Sr. VP | 10000 0.0049% | $47,500.00 | 2 | 2 | |
| PYKETT MARK JEROME | director | 8000 0.0039% | $38,000.00 | 1 | 0 |
$831,902,292 | 108 | 9.34% | $1.2B | |
Savara Inc. (SVRA) | $15,410,062 | 81 | 39.69% | $975.93M |
$5,911,307 | 70 | -1.38% | $884.8M | |
$11,663,618 | 57 | 32.20% | $934.29M | |
$276,808,393 | 17 | -6.69% | $888.11M |
| Increased Positions | 99 | +81.82% | 56M | +34.55% |
| Decreased Positions | 54 | -44.63% | 16M | -9.63% |
| New Positions | 47 | New | 32M | New |
| Sold Out Positions | 14 | Sold Out | 3M | Sold Out |
| Total Postitions | 166 | +37.19% | 202M | +24.92% |
| Nea Management Company, Llc | $138,018.00 | 12.06% | 24.47M | 0 | 0% | 2025-09-30 |
| Bain Capital Life Sciences Investors, Llc | $99,268.00 | 8.67% | 17.6M | 0 | 0% | 2025-09-30 |
| Vr Adviser, Llc | $71,521.00 | 6.25% | 12.68M | +4M | +42.74% | 2025-09-30 |
| Tcg Crossover Management, Llc | $69,723.00 | 6.09% | 12.36M | 0 | 0% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $64,647.00 | 5.65% | 11.46M | 0 | 0% | 2025-09-30 |
| Nantahala Capital Management, Llc | $49,493.00 | 4.32% | 8.78M | +450,000 | +5.41% | 2025-09-30 |
| Blackrock, Inc. | $47,648.00 | 4.16% | 8.45M | -1M | -13.58% | 2025-09-30 |
| Vanguard Group Inc | $46,886.00 | 4.1% | 8.31M | -140,786 | -1.67% | 2025-09-30 |
| Deerfield Management Company, L.P. | $44,917.00 | 3.92% | 7.96M | 0 | 0% | 2025-09-30 |
| Vestal Point Capital, Lp | $22,645.00 | 1.98% | 4.01M | -7M | -63.55% | 2025-09-30 |